Latest Humira dispute highlights biosimilar trade secrets dangers

AbbVie’s clash with an adalimumab biosimilar producer is the latest in a string of lawsuits showing why biologics originators and imitators need strategies to protect proprietary information

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

20 Oct 2021

@IAM_Alerts Our 5G licensing rates will be ready before mass vehicle roll-out begins, says top @AvanciCompany executive, as the… https://t.co/bRjTXpR4Ho Read more

19 Oct 2021

@IAM_Alerts RT @marconi: Last week, our @Avanci colleague Luke McLeroy spoke at @IAM_Alerts' #AutoIPUSA event in Detroit. On Nov 2, Laurie Fitzgerald… Read more

19 Oct 2021

@IAM_Alerts After a tough 2020 for med-tech deal-making, diagnostic innovation buyouts are driving a resurgence in IP-rich acqu… https://t.co/M44uKPtagj Read more

19 Oct 2021

@IAM_Alerts Ericsson posts strong licensing quarter as it heads into an all-important renewal with Apple https://t.co/xbbxWFsscH https://t.co/KZpjln1pcM Read more

Latest Humira dispute highlights biosimilar trade secrets dangers

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter